featured
Impact of Initial Tumor Response on Survival Outcomes in Patients With HER2+ Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Breast Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial
Clin. Breast Cancer 2024 Feb 21;[EPub Ahead of Print], V Debien, E Agostinetto, M Bruzzone, M Ceppi, D Martins-Branco, C Molinelli, F Jacobs, G Nader-Marta, M Lambertini, E de AzambujaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.